Found: 23
Select item for more details and to access through your institution.
Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.
- Published in:
- Infectious Diseases & Therapy, 2018, v. 7, n. 2, p. 261, doi. 10.1007/s40121-018-0197-y
- By:
- Publication type:
- Article
Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV‐Infected Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 6, p. 802, doi. 10.1002/cpdd.649
- By:
- Publication type:
- Article
Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 195, doi. 10.1002/cpdd.315
- By:
- Publication type:
- Article
Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
- Published in:
- Drugs in R&D, 2018, v. 18, n. 1, p. 55, doi. 10.1007/s40268-017-0222-8
- By:
- Publication type:
- Article
Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19628
- By:
- Publication type:
- Article
ABT-089 demonstrates efficacy in a human model of cognition and good tolerability in subjects with Alzheimer's disease taking acetylcholinesterase inhibitors
- Published in:
- 2009
- By:
- Publication type:
- Abstract
Evaluation of P-glycoprotein-Mediated Renal Drug Interactions in an NDR1-MDCK Model.
- Published in:
- Pharmacotherapy, 2003, v. 23, n. 4, p. 436, doi. 10.1592/phco.23.4.436.32125
- By:
- Publication type:
- Article
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD.
- Published in:
- Neuropsychopharmacology, 2013, v. 38, n. 3, p. 405, doi. 10.1038/npp.2012.194
- By:
- Publication type:
- Article
Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 4, p. 986, doi. 10.1002/cpt.2291
- By:
- Publication type:
- Article
Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 5, p. 1314, doi. 10.1002/cpt.2096
- By:
- Publication type:
- Article
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Exposure–Clinical Response Analysis of Paricalcitol in Patients With Chronic Kidney Disease (Stage 5) on Hemodialysis or Peritoneal Dialysis.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Exposure–Clinical Response Analysis of Paricalcitol in Patients With Chronic Kidney Disease (Stage 5) on Hemodialysis or Peritoneal Dialysis.
- Published in:
- Journal of Clinical Pharmacology, 2012, v. 52, n. 8, p. 1162, doi. 10.1177/0091270011412966
- By:
- Publication type:
- Article
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Use of Real‐World Evidence in a Virtual Bridging Analysis for a Human Epidermal Growth Factor Receptor 2–Targeted Antibody–Drug Conjugate in Gastric Cancer.
- Published in:
- Journal of Clinical Pharmacology, 2023, v. 63, n. 11, p. 1244, doi. 10.1002/jcph.2297
- By:
- Publication type:
- Article
Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2‐Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure–Response Analysis.
- Published in:
- Journal of Clinical Pharmacology, 2023, v. 63, n. 11, p. 1232, doi. 10.1002/jcph.2295
- By:
- Publication type:
- Article
Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 4, p. 557, doi. 10.1002/jcph.1347
- By:
- Publication type:
- Article
Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 11, p. 1468, doi. 10.1002/jcph.1274
- By:
- Publication type:
- Article
Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 11, p. 1479, doi. 10.1002/jcph.1262
- By:
- Publication type:
- Article
A Review of Daclatasvir Drug-Drug Interactions.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
- Published in:
- Journal of Gastroenterology & Hepatology, 2016, v. 31, n. 11, p. 1860, doi. 10.1111/jgh.13379
- By:
- Publication type:
- Article
Toxicokinetic Study of Recombinant Human Heparin-Binding Epidermal Growth Factor-Like Growth Factor (rhHB-EGF) in Female Sprague Dawley Rats.
- Published in:
- Pharmaceutical Research, 2008, v. 25, n. 3, p. 542, doi. 10.1007/s11095-007-9392-3
- By:
- Publication type:
- Article